Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E, Group T. Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma. Cancer 2001, 94: 25-36. PMID: 11815957, DOI: 10.1002/cncr.10201.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionMetastatic breast carcinomaClinical congestive heart failureTLC DConventional doxorubicinBreast carcinomaTreatment groupsResponse rateMedian cumulative doxorubicin doseProgesterone receptor-positive patientsWorld Health Organization criteriaCumulative doxorubicin doseOnset of cardiotoxicityPrimary safety endpointReceptor-positive patientsPrimary efficacy endpointRandomized multicenter trialFirst-line therapyFirst-line treatmentPalmar-plantar erythrodysesthesiaCongestive heart failureRelevant prognostic factorsVentricular ejection fractionOverall response rateComparable antitumor activityLiposomal anthracyclines for breast cancer
Sparano J, Winer E. Liposomal anthracyclines for breast cancer. Seminars In Oncology 2001, 28: 32-40. PMID: 11552228, DOI: 10.1016/s0093-7754(01)90197-6.Peer-Reviewed Original ResearchConceptsBreast cancerLiposomal anthracyclinesAdvanced-stage breast cancerStage breast cancerConventional anthracyclinesTLC DLiposomal daunorubicinCardiac toxicityConventional doxorubicinLiposomal doxorubicinPreclinical modelsAnthracyclinesCancer typesCytotoxic agentsNormal tissuesCancerFurther studiesChronic toxicityDoxorubicinTreatmentToxicityLiposomal doxorubicin preparationsAgentsCyclophosphamideVinorelbine